[조사자료] 글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타

■ 영문 제목 : Generic Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer, Diabetes, Others), By Route of Administration (Oral, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032
	■ 상품코드 : ALD23SEP154 ■ 조사/발행회사 : Allied Market Research ■ 발행일 : 2023년 6월 ■ 페이지수 : 252 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 세계

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD5,730 ⇒환산￦7,735,500	견적의뢰/주문/질문
5 User	USD6,450 ⇒환산￦8,707,500	견적의뢰/주문/질문
Enterprise User	USD9,600 ⇒환산￦12,960,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 제네릭 의약품 시장은 2022년에 385,320,00백만 달러로 평가되었으며 2032년에는 835,706,50백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 8.1%의 연평균 성장률을 보일 것으로 전망됩니다.제네릭 의약품은 용량 형태, 효능, 투여 방식, 품질, 성능 특성 및 의도 된 목적 측면에서 이전에 마케팅 승인을받은 브랜드 의약품과 유사한 의약품입니다. 제네릭 의약품은 브랜드 의약품에 비해 저렴한 가격으로 구입할 수 있습니다.

제네릭 의약품 시장의 성장은 당뇨병, 암, 심혈관 질환과 같은 만성 질환의 유병률 급증에 의해 주도되고 있습니다. 세계 암 연구 기금(WCRF)에 따르면 2020년 전 세계적으로 약 1,810만 건의 암이 발생했으며, 이 중 남성은 930만 건, 여성은 880만 건으로 추정됩니다. 또한 제네릭 의약품의 저렴한 가격과 최신 제품 승인 및 제품 출시도 시장 성장에 기여하고 있습니다. 예를 들어, 2021년 2월 연구 중심의 글로벌 종합 제약회사인 글렌마크 파마슈티컬스(Glenmark Pharmaceuticals)는 인도에서 신장암 치료용 수니티닙 경구 캡슐의 제네릭 버전인 수팁(SUTIB)을 출시했다고 발표했습니다.
또한 브랜드 의약품의 비용 상승, 제네릭 의약품에 대한 높은 수요, 제네릭 의약품에 대한 인식 상승이 시장 성장에 기여하고 있습니다. 또한 글로벌 제네릭 의약품 시장의 저명한 업체들은 시장에서의 입지를 강화하고 경쟁 환경을 유지하기 위해 제품 출시, 인수, 제네릭 의약품의 발전을 위한 R&D 투자와 같은 다양한 전략을 채택했습니다.

또한 당뇨병 유병률의 놀라운 증가, 제네릭 의약품의 기술 발전, 노인 인구의 증가는 시장 성장을 이끄는 주요 요인 중 일부입니다. 노인 인구는 당뇨병과 고혈압과 같은 만성 질환에 더 취약합니다. 그러나 제네릭 의약품의 일관성 및 안정성과 관련된 우려는 시장 성장을 방해합니다. 반대로, 인구 사이에서 제네릭 의약품에 대한 인식이 높아짐에 따라 가까운 장래에 시장 성장을위한 수익성있는 기회를 제공 할 것으로 예상됩니다. 또한 의료 인프라의 상당한 개선과 함께 제네릭 의약품 분야의 광범위한 연구 개발 활동은 예측 기간 동안 시장 확장을위한 새로운 길을 열 것으로 예상됩니다.

제네릭 의약품 시장은 치료 용도, 투여 경로, 유통 채널 및 지역으로 세분화됩니다. 치료 용도에 따라 시장은 심혈관, 전염병, 암, 당뇨병 및 기타로 나뉩니다. 투여 경로에 따라 경구용, 주사제, 기타로 시장이 분류됩니다.

유통 채널에 따라 병원 약국, 소매 약국 및 온라인 제공 업체로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인 및 기타 유럽 지역), 아시아 태평양(일본, 중국, 호주, 인도, 한국 및 기타 아시아 태평양), 중남미/중동/아프리카(브라질, 남아프리카공화국, 사우디아라비아 및 기타 중남미/중동/아프리카)에서 시장이 연구되고 있습니다.
보고서에 프로파일링된 주요 기업으로는 Amneal Pharmaceuticals, Aurobindo Pharma, Cipla, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Sandoz International GmbH, Sun Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Viatris Inc.등이 있습니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 제네릭 의약품 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 제네릭 의약품 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 잠재력을 강조합니다.
제네릭 의약품 시장 세분화에 대한 심층 분석은 일반적인 시장 기회를 결정하는 데 도움이 됩니다.
글로벌 시장에 대한 매출 기여도에 따라 각 지역의 주요 국가를 매핑합니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 제네릭 의약품 시장 동향, 주요 업체, 시장 세그먼트, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 세그먼트
유통 채널별
병원 약국
소매 약국
온라인 제공업체

치료 용도별
심혈관 질환
감염성 질환
암
당뇨병
기타

투여 경로별
경구
주사제
기타

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
중국
일본
인도
호주
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Amneal Pharmaceuticals, Inc.
○ Aurobindo Pharma
○ Cipla Ltd
○ GlaxoSmithKline plc
○ Hikma Pharmaceuticals PLC
○ Lupin
○ Novartis AG
○ Sun Pharmaceutical Industries Ltd
○ Teva Pharmaceutical Industries Limited
○ Viatris Inc.

■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 제네릭 의약품 시장, 치료 용도별
CHAPTER 5 : 제네릭 의약품 시장, 투여 경로별
CHAPTER 6 : 제네릭 의약품 시장, 유통 채널별
CHAPTER 7 : 제네릭 의약품 시장, 지역별
CHAPTER 8 : 경쟁 현황
CHAPTER 9 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic diseases
3.4.1.2. Availability of low-cost generic drugs
3.4.1.3. Upsurge in geriatric population

3.4.2. Restraints
3.4.2.1. Concern related to the quality of generic drugs

3.4.3. Opportunities
3.4.3.1. Patent expiry of branded drugs and new product approvals

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Cardiovascular
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Infectious Diseases
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cancer
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Diabetes
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injections
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: GENERIC DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapeutic Application
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapeutic Application
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapeutic Application
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Therapeutic Application
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapeutic Application
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapeutic Application
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapeutic Application
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapeutic Application
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapeutic Application
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Therapeutic Application
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Therapeutic Application
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapeutic Application
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapeutic Application
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapeutic Application
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapeutic Application
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Therapeutic Application
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Therapeutic Application
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Therapeutic Application
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapeutic Application
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapeutic Application
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapeutic Application
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Therapeutic Application
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Therapeutic Application
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Amneal Pharmaceuticals, Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. GlaxoSmithKline plc
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Teva Pharmaceutical Industries Limited
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Viatris Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Sun Pharmaceutical Industries Ltd
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Cipla Ltd
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Hikma Pharmaceuticals PLC
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Lupin
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Aurobindo Pharma
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 02. GENERIC DRUGS MARKET FOR CARDIOVASCULAR, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GENERIC DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GENERIC DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GENERIC DRUGS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 08. GENERIC DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GENERIC DRUGS MARKET FOR INJECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 12. GENERIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GENERIC DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GENERIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 21. U.S. GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 22. U.S. GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. CANADA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 24. CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 25. CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. MEXICO GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 27. MEXICO GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 28. MEXICO GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 30. EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. EUROPE GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 34. GERMANY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. FRANCE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 37. FRANCE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 38. FRANCE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. UK GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 40. UK GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 41. UK GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. ITALY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 43. ITALY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. ITALY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. SPAIN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 46. SPAIN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 47. SPAIN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. CHINA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 56. CHINA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 57. CHINA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. JAPAN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 59. JAPAN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. INDIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 62. INDIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 63. INDIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 74. LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. LAMEA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 78. BRAZIL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. BRAZIL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. AMNEAL PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 90. AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 91. AMNEAL PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 92. AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 93. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 94. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 95. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 96. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY EXECUTIVES
TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 105. VIATRIS INC.: KEY EXECUTIVES
TABLE 106. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 107. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 108. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 109. VIATRIS INC.: KEY STRATERGIES
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 114. CIPLA LTD: KEY EXECUTIVES
TABLE 115. CIPLA LTD: COMPANY SNAPSHOT
TABLE 116. CIPLA LTD: PRODUCT SEGMENTS
TABLE 117. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 118. HIKMA PHARMACEUTICALS PLC: KEY EXECUTIVES
TABLE 119. HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 120. HIKMA PHARMACEUTICALS PLC: PRODUCT SEGMENTS
TABLE 121. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 122. LUPIN: KEY EXECUTIVES
TABLE 123. LUPIN: COMPANY SNAPSHOT
TABLE 124. LUPIN: PRODUCT SEGMENTS
TABLE 125. LUPIN: PRODUCT PORTFOLIO
TABLE 126. LUPIN: KEY STRATERGIES
TABLE 127. AUROBINDO PHARMA: KEY EXECUTIVES
TABLE 128. AUROBINDO PHARMA: COMPANY SNAPSHOT
TABLE 129. AUROBINDO PHARMA: PRODUCT SEGMENTS
TABLE 130. AUROBINDO PHARMA: PRODUCT PORTFOLIO

※본 조사보고서 [글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타] (코드 : ALD23SEP154) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 의약품 약물 전달 시장 (2023-2032) : 경구 약물 전달, 비강 약물 전달, 안구 약물 전달, 국소 약물 전달, 기타
ALD23SEP156 / Allied Market Research / 2023년 6월 / 글로벌 의약품 약물 전달 시장은 2022년에 14억 9,872만 달러로 평가되었으며 2023년부터 2032년까지 4.4%의 연평균 성장률을 보이며 2032년에는 2조 3,727억 달러에 달할 것으로 예상됩니다. 약물 전달은 원하는 치료 효과를 얻기 위해...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 의약품 약물 전달 시장, 투여 경로별 CHAPTER 5 : 의약품 약물 전달 시장, 용도별 CHAPTER 6 : 의약품 약물 전달 시장, 지역별 CHAPTER 7 : 경쟁 현황 CHAPTER 8 : 기업 정보...

글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...

글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타
ALD23SEP123 / Allied Market Research / 2023년 4월 / 글로벌 근골격계 질환 (MSD) 치료제 시장은 2022년 834억 7,424만 달러 규모였으며 2023년부터 2032년까지 4.2%의 연평균 성장률을 보이며 2032년에는 126억 3,022만 달러에 달할 것으로 예상됩니다. 근골격계 질환(MSD)은 근육, 뼈, 관절에 영향을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 근골격계 질환(MSD) 치료제 시장, 약품 유형별 CHAPTER 5 : 근골격계 질환(MSD) 치료제 시장, 투여 경로별 CHAPTER 6 : 근골격계 질환(MSD) 치료제 시장, 유통 채널별 CHAPTER 7 : 근골격계 질환(MSD) 치료제 시장, 지역별 CHAPTER 8...

글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...

글로벌 혈전 용해제 시장 (2023-2032) : 혈전 용해제, 항혈소판제, 항응고제, 항응고제, 기타
ALD23SEP170 / Allied Market Research / 2023년 6월 / 글로벌 혈전 용해제 시장은 2022년 28,616.4억 달러에서 2023년부터 2032년까지 8.2%의 연평균 성장률로 성장하여 2032년에는 60,009.20억 달러에 달할 것으로 예상됩니다.혈전 용해제 또는 섬유소 용해제라고도 하는 혈전 용해제는 혈전증이라는 의학적 질환에서 혈전을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 혈전 용해제 시장, 제품별 CHAPTER 5 : 혈전 용해제 시장, 질환별 CHAPTER 6 : 혈전 용해제 시장, 투여 경로별 CHAPTER 7 : 혈전 용해제 시장, 유통 채널별 CHAPTER 8 : 혈전 용해제 시장, 지역별...